ID=wsj_0468.1 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP G.D. N_159/N_159>) (<T N 1 2> (<L N/N NNP NNP Searle N_152/N_152>) (<T N 1 2> (<L N/N CC CC & N_145/N_145>) (<L N NNP NNP Co. N>) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_8)/S[dcl]_9>) (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_136/N_136>) (<T N 1 2> (<L N NNP NNP Food N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<T N 1 2> (<L N/N NNP NNP Drug N_127/N_127>) (<L N NNP NNP Administration N>) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBD VBD approved (S[dcl]\NP_16)/NP_17>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_24/N_24>) (<L N NN NN sale N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_32\NP_32)/NP_33>) (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Kerlone N>) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_50/N_50>) (<T N 1 2> (<L N/N NN NN hypertension N_45/N_45>) (<L N NN NN drug N>) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN developed S[pss]\NP_55>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN by ((S_68\NP_63)_68\(S_68\NP_63)_68)/NP_69>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_83/N_83>) (<T N 1 2> (<L N/N JJ JJ joint N_78/N_78>) (<L N NN NN venture N>) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN between (NP_91\NP_91)/NP_92>) (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Searle N>) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_109/N_109>) (<T N 1 2> (<L N/N JJ JJ French N_104/N_104>) (<L N NN NN concern N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_0468.2 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Searle N>) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_377/N_377>) (<L N NN NN unit N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_385\NP_385)/NP_386>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Monsanto N_395/N_395>) (<L N NNP NNP Co. N>) ) ) ) ) ) ) (<L , , , , ,>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_135)/S[dcl]_136>) (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_367/N_367>) (<T N 1 2> (<L N/N NN NN beta-blocker N_362/N_362>) (<T N 1 2> (<L N/N JJ JJ high-blood-pressure N_355/N_355>) (<T N 1 2> (<L N/N NN NN drug N_348/N_348>) (<L N NNP NNP Kerlone N>) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBZ VBZ is (S[dcl]\NP_143)/NP_144>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_158/N_158>) (<T N 1 2> (<L N/N JJ JJ first N_153/N_153>) (<L N NN NN product N>) ) ) (<T NP\NP 0 1> (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_167)/(S[b]_168\NP_167:B)_168>) (<T S[b]\NP 0 2> (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB reach (S[b]\NP_175)/NP_176>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_183/N_183>) (<L N NN NN market N>) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN through ((S_196\NP_191)_196\(S_196\NP_191)_196)/NP_197>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP Lorex N_206/N_206>) (<L N NNP NNP Pharmaceuticals N>) ) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_221/N_221>) (<T N 1 2> (<L N/N NNP NNP U.S. N_216/N_216>) (<L N NN NN company N>) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 1 2> (<L (S\NP)/(S\NP) RB RB jointly (S_327\NP_322)_327/(S_327\NP_322)_327>) (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN owned S[pss]\NP_226>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN by ((S_239\NP_234)_239\(S_239\NP_234)_239)/NP_240>) (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Searle N>) ) (<T NP[conj] 1 2> (<L conj CC CC and conj>) (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Synthelabo N>) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_267/N_267>) (<T N 1 2> (<L N/N JJ JJ French N_262/N_262>) (<T N 1 2> (<L N/N JJ JJ pharmaceutical N_255/N_255>) (<L N NN NN concern N>) ) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN owned S[pss]\NP_272>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN by ((S_285\NP_280)_285\(S_285\NP_280)_285)/NP_286>) (<T NP 1 2> (<T NP[nb]/N 1 2> (<T NP 0 1> (<L N NNP NNP France N>) ) (<L (NP[nb]/N)\NP POS POS 's (NP[nb]_302/N_302)\NP_303>) ) (<T N 1 2> (<L N/N NNP NNP L'Oreal N_295/N_295>) (<L N NNP NNP S.A N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
